Ovagen research monograph — the liver/GI Khavinson tripeptide (EDL) and its single-group evidence base

Ovagen is one of the Khavinson "short peptide bioregulators" — a synthetic tripeptide (Glu-Asp-Leu, "EDL") in the "Cytogen" bioregulator family, targeting liver and gastrointestinal tissue.

Class

Khavinson peptide bioregulator; synthetic tripeptide (Glu-Asp-Leu / EDL), liver- and GI-targeted. Single compound.

Mechanism

Ovagen is one of the Khavinson short peptide bioregulators — very short synthetic peptides (here a tripeptide, EDL) proposed to act as tissue-specific gene-expression modulators at low, near-physiological concentrations. The Khavinson model holds that even a tripeptide carries tissue-targeting information (via charge distribution, hydrogen-bonding and conformation) that lets it reach DNA and modulate transcription of genes tied to the target tissue — for Ovagen, hepatocytes (liver) and GI epithelium. This "peptide bioregulation" mechanism is a hypothesis advanced largely by one research group and is not broadly established in mainstream molecular biology.

Research summary

Important epistemic caveat: essentially all of the Ovagen / Khavinson-bioregulator literature originates from Professor Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology and affiliated Russian biogerontology researchers — effectively a single institute and one school of thought. Independent replication outside this group is scarce. Within that literature, Ovagen has been studied for normalizing hepatic gene-expression and liver/GI function in aging and stress models. The evidence is overwhelmingly animal-model and mechanistic; rigorous controlled human efficacy data are absent. (Knowledge-base note: external databases return unrelated hits for "Ovagen" — a homeopathic menstrual-relief product and a veterinary superovulation hormone share the name; neither pertains to this peptide.)

Studied protocols

No standardized research protocol. Khavinson-tradition bioregulators are typically studied/used as short courses (often ~10-day cycles, repeated periodically) at low microgram-range doses, by injection or — for the consumer "Cytogen" lingual forms — sublingually. These reflect the bioregulator usage tradition, not validated dosing from controlled trials.

Stacking research

No controlled stacking studies. In the Khavinson tradition, organ-specific peptides are often combined (one peptide per target organ) as a "bioregulation" regimen, but combination efficacy has not been demonstrated in controlled research.

Clinical / safety context

Not an approved drug in the US/EU; sold research-use-only (and as a supplement-style "peptide bioregulator" in some markets). Reported as well tolerated in the originating literature, but there is no rigorous independent safety dataset. Treat safety claims as unverified outside the Khavinson group's reports.

Evidence quality — Limited / single-group

Mechanistically interesting but evidentiarily weak from an independent standpoint: the data come almost entirely from one institute, are mostly animal/mechanistic, and lack independent replication and controlled human trials. The indexed external documents for this compound are name-collision noise, not real evidence.

Notes

Ovagen = EDL tripeptide (Glu-Asp-Leu), liver/GI-targeted Khavinson bioregulator; sold as injectable lyophilized peptide and as sublingual "Cytogen Ovagen" consumer forms. Same family as Thymogen, Chonluten, Prostamax, Epitalon. Do not confuse with the veterinary "Ovagen" (ovine-FSH superovulation product) or homeopathic "R18 Ovagen."